Bisoprolol Treatment and Adherence in Pediatric Patients With Genotype-Positive Long QT Syndrome.

Authors

Eemil Taipalus, Minna Mecklin, Antti Tikkakoski, Tuija Poutanen, Kaisa Ylänen

Published in

Journal of arrhythmia. Volume 42. Issue 4. Pages e70422. Epub Jul 14, 2026.

Abstract

Non-selective beta-blockers, such as propranolol, are highly effective in reducing arrhythmia risk in long QT Syndrome (LQTS). The study aim was to evaluate the use of beta-blockers, especially beta-1-selective bisoprolol, and their efficacy in Finnish children with genotype-positive LQTS type 1 or 2.
We retrospectively reviewed the medical records of children with genetically confirmed LQTS1 or LQTS2 diagnosis, who were treated at Tampere University Hospital in Finland between 2006 and 2020. Data on cardiac events, beta-blocker use and adherence, ECG, clinical exercise tests, and genetic testing were collected.
Eighty-eight children were diagnosed with a genotype-positive type 1 or 2 LQTS, and 84% of them had a family history of LQTS associated gene mutations. Four Finnish founder mutations accounted for 68% of the cases. At diagnosis, 63% had a normal QTc interval. No cardiac events occurred during follow-up among patients receiving beta-blocker therapy. For children aged 0-7 years, propranolol was the primary medication in 90% of cases, and for > 7-year-olds, bisoprolol was used in 77% of cases. At the last follow-up visit, 87/88 were on beta-blockers, most commonly bisoprolol (66%). Medication adherence was high, with 84% of patients using beta-blockers as prescribed. In clinical exercise tests, maximal heart rate remained < 160 beats per minute in 76% of tests, indicating effective beta-blockade.
Cascade screening identified asymptomatic patients, most with normal QTc intervals. Bisoprolol was the most commonly used beta-blocker with good adherence, effective heart rate control, and no cardiac events observed during follow-up among these Finnish children with LQTS.

PMID:
42454241
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.